Amgen announced Amjevita, a biosimilar to Humira, is now available in the United States. Amjevita was the first biosimilar to Humira approved by the FDA, in 2016.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMGN:
- AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
- Amgen lays off 300 employees, or 1.2% of workforce, Reuters reports
- Can Amgen (AMGN) Q4 Earnings Beat Street Expectations?
- Warren writes FTC over concerns of two pharma deals, Reuters reports
- Amgen price target cut at Piper on lower Otezla estimates